Ginkgo Bioworks to go public in SPAC deal worth over $1.6B

By The Science Advisory Board staff writers

September 15, 2021 -- Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition company (SPAC).

The deal was approved by Soaring Eagle's shareholders on September 14. Subject to customary closing conditions, Soaring Eagle anticipates that the deal with Gingko will close on September 16. Following closing, Soaring Eagle will change its name to Ginkgo Bioworks Holdings.

The combined company's shares of class A common stock and public warrants are expected to begin trading on the New York Stock Exchange on September 17, 2021, under the ticker symbols DNA and DNA.WS, respectively.

If you like this content, please share it with a colleague!

Related Reading

Biogen, Ginkgo partner on enhanced AAV manufacturing for gene therapies
Biogen and Ginkgo Bioworks will collaborate to develop improved methods for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity...

Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus...